Selection of chemotherapy for XXXX is facilitated by new therapeutic strategies.

@entity1 @entity66 @entity5 @entity470 @entity1149
Nowadays, advanced @entity1149 is still an incurable disease. Recent researches have led to considerable progress in the treatment of @entity1149 . This article reviews the main studies on chemotherapy on @entity1149 and discusses the new therapeutic strategies available to date. @entity66 ( @entity66 ) is necessary in chemotherapy for @entity5 . The proportion of population with responders or @entity66 basically maintained similar regardless of regimens. The overall survival after chemotherapy for @entity1 with @entity66 was lower than @entity1 with responders, and higher than @entity1 with progressive disease. Greater benefits could be achieved in @entity1 with effective induction chemotherapy using chemotherapeutic agents for maintenance therapy, whereas the benefits were relatively small for @entity1 with @entity66 . It has been found that @entity470 ( @entity470 ) mutation status had certain correlation with the efficacy of chemotherapy. First-line chemotherapy has shown advantages in effective rate and progression free survival on @entity470 mutant. @entity470 mutation produced significant effects on the efficacy of postoperative adjuvant chemotherapy. @entity1 with @entity470 mutation had a higher effective rate than wild-type @entity470 @entity1 , and @entity1 with responders had a greater benefit in progression free survival from maintenance therapy. However, it is still necessary to carry out more careful and deeper studies and analyses on traditional cytotoxic chemotherapy, to further optimize cytotoxic chemotherapy and to use molecular targeted agents with different mechanisms.
